Editorial: Updates on toll-like receptors in cancer immunity and immunotherapy

Front Immunol. 2023 Nov 13:14:1331317. doi: 10.3389/fimmu.2023.1331317. eCollection 2023.

Authors

Bettina Hoden¹, Yasuhiro Nagai², Laura Schuettpelz³, Dekai Zhang¹

Affiliations

¹ Center for Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M University, Houston, TX, United States.
² Cancer Research Unit, Sumitomo Pharma Co. Ltd., Osaka, Japan.
³ Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States.

No abstract available

Keywords: TLR signaling; cancer; cancer immunity; immunotherapy; toll-like receptor (TLR).

Publication types

Editorial

MeSH terms

Humans
Immunotherapy
Neoplasms* / therapy
Toll-Like Receptors*

Substances

Toll-Like Receptors

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.